← Back to Screener
Enveric Biosciences, Inc. Common Stock (ENVB)
Price$2.26
Value ScoreB
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-76.61%
Price vs S&P 500 (4W)-47.33%
VGM Score44.13
Market Capitalization$8.47M
All Metrics
Book Value / Share (Quarterly)$2.68
P/TBV (Annual)2.35x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.35%
Cash Flow / Share (Quarterly)$-4.24
Price vs S&P 500 (YTD)-47.57%
Gross Margin (TTM)20.42%
Net Profit Margin (TTM)-14.05%
EPS (TTM)$-22.04
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-22.04
EPS (Annual)$-26.21
ROI (Annual)-209.98%
Gross Margin (Annual)20.42%
Net Profit Margin (5Y Avg)-18.30%
Cash / Share (Quarterly)$2.60
Revenue Growth QoQ (YoY)-11.87%
ROA (Last FY)-172.14%
Revenue Growth TTM (YoY)-7.16%
EBITD / Share (TTM)$-11.95
ROE (5Y Avg)-408.09%
Operating Margin (TTM)-15.88%
Cash Flow / Share (Annual)$-7.67
P/B Ratio1.67x
P/B Ratio (Quarterly)0.72x
Net Income / Employee (Annual)$-1,754,400
EV / Revenue (TTM)0.09x
Net Interest Coverage (TTM)-79744.36x
ROA (TTM)-177.47%
EPS Incl Extra (Annual)$-26.21
Current Ratio (Annual)5.38x
Quick Ratio (Quarterly)10.66x
3-Month Avg Trading Volume2.89M
52-Week Price Return-84.16%
Revenue / Employee (TTM)$7,984,000
Tangible BV / Share (Quarterly)$8.66
P/S Ratio (Annual)0.21x
Asset Turnover (Annual)1.58x
52-Week High$17.64
Operating Margin (5Y Avg)-16.30%
EPS Excl Extra (Annual)$-26.21
Tangible BV CAGR (5Y)-26.11%
26-Week Price Return-60.68%
Quick Ratio (Annual)5.14x
13-Week Price Return-0.86%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.67x
Enterprise Value$3.56M
Asset Turnover (TTM)1.43x
Book Value / Share Growth (5Y)-25.46%
Revenue / Employee (Annual)$7,982,000
Inventory Turnover (Annual)2.60x
Pretax Margin (Annual)-13.08%
Cash / Share (Annual)$4.41
3-Month Return Std Dev230.36%
Gross Margin (5Y Avg)23.50%
Net Income / Employee (TTM)$-1,644,100
ROE (Last FY)-209.98%
Net Interest Coverage (Annual)-9332.56x
EPS Basic Excl Extra (Annual)$-26.21
P/FCF (TTM)49.81x
Receivables Turnover (TTM)5.60x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-22.04
Receivables Turnover (Annual)5.60x
ROI (TTM)-220.99%
P/S Ratio (TTM)0.21x
Pretax Margin (5Y Avg)-18.38%
Revenue / Share (Annual)$3991.00
Tangible BV / Share (Annual)$27.44
Price vs S&P 500 (52W)-112.37%
Year-to-Date Return-36.64%
5-Day Price Return4.07%
EPS Normalized (Annual)$-26.21
ROA (5Y Avg)-232.54%
Net Profit Margin (Annual)-14.03%
Month-to-Date Return-41.77%
Cash Flow / Share (TTM)$-10.58
EBITD / Share (Annual)$-25.61
Operating Margin (Annual)-15.84%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-408.09%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-22.04
P/TBV (Quarterly)1.37x
P/B Ratio (Annual)0.52x
Inventory Turnover (TTM)19.00x
Pretax Margin (TTM)-13.05%
Book Value / Share (Annual)$3.94
Price vs S&P 500 (13W)-10.61%
Beta1.12x
P/FCF (Annual)25.66x
Revenue / Share (TTM)$3992.00
ROE (TTM)-220.99%
52-Week Low$1.71
vGradeB
gGradeD
mGradeD
vgmGradeC
Show chart for
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENVBEnveric Biosciences, Inc. Common Stock | B | D | D | $2.26 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Enveric Biosciences develops novel small-molecule therapeutics targeting depression, anxiety, addiction, and other psychiatric disorders through neuroplastogenicity. Its lead program, EB-003, is a first-in-class candidate designed to promote neuroplasticity without inducing hallucinations. The company is also advancing EB-002, a synthetic psilocin prodrug, as a next-generation treatment for psychiatric disorders.